Kumaraguru Raja
Stock Analyst at Brookline Capital
(0.27)
# 4,020
Out of 4,728 analysts
15
Total ratings
25%
Success rate
-36.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kumaraguru Raja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QNCX Quince Therapeutics | Initiates: Buy | $9 | $1.71 | +426.32% | 1 | Dec 18, 2024 | |
| PALI Palisade Bio | Initiates: Buy | $38 | $1.75 | +2,071.43% | 1 | Nov 20, 2024 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $8 | $3.55 | +125.35% | 1 | Jun 7, 2024 | |
| FBRX Forte Biosciences | Initiates: Buy | $100 | $14.62 | +583.99% | 2 | May 30, 2024 | |
| HEPA Hepion Pharmaceuticals | Downgrades: Hold | n/a | $0.48 | - | 1 | Dec 7, 2023 | |
| OTLK Outlook Therapeutics | Downgrades: Hold | n/a | $2.16 | - | 1 | Aug 30, 2023 | |
| ADIL Adial Pharmaceuticals | Reiterates: Buy | $150 | $1.02 | +14,605.88% | 2 | Jul 11, 2023 | |
| GNTA Genenta Science | Assumes: Buy | $15 | $4.24 | +254.02% | 1 | Jun 29, 2023 | |
| RAIN Rain Enhancement Technologies | Reinstates: Buy | $21 | $4.33 | +384.99% | 1 | Jan 31, 2023 | |
| MNPR Monopar Therapeutics | Reinstates: Buy | $90 | $24.98 | +260.29% | 1 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $31 | $0.74 | +4,069.47% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,360 | $1.44 | +233,233.33% | 1 | Sep 21, 2021 |
Quince Therapeutics
Dec 18, 2024
Initiates: Buy
Price Target: $9
Current: $1.71
Upside: +426.32%
Palisade Bio
Nov 20, 2024
Initiates: Buy
Price Target: $38
Current: $1.75
Upside: +2,071.43%
SAB Biotherapeutics
Jun 7, 2024
Initiates: Buy
Price Target: $8
Current: $3.55
Upside: +125.35%
Forte Biosciences
May 30, 2024
Initiates: Buy
Price Target: $100
Current: $14.62
Upside: +583.99%
Hepion Pharmaceuticals
Dec 7, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.48
Upside: -
Outlook Therapeutics
Aug 30, 2023
Downgrades: Hold
Price Target: n/a
Current: $2.16
Upside: -
Adial Pharmaceuticals
Jul 11, 2023
Reiterates: Buy
Price Target: $150
Current: $1.02
Upside: +14,605.88%
Genenta Science
Jun 29, 2023
Assumes: Buy
Price Target: $15
Current: $4.24
Upside: +254.02%
Rain Enhancement Technologies
Jan 31, 2023
Reinstates: Buy
Price Target: $21
Current: $4.33
Upside: +384.99%
Monopar Therapeutics
Dec 9, 2022
Reinstates: Buy
Price Target: $90
Current: $24.98
Upside: +260.29%
May 18, 2022
Maintains: Buy
Price Target: $29 → $31
Current: $0.74
Upside: +4,069.47%
Sep 21, 2021
Initiates: Buy
Price Target: $3,360
Current: $1.44
Upside: +233,233.33%